{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 26,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a structured layout to present the company's oncology portfolio, categorizing drugs by their therapeutic focus and market position.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/8",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.53,
        "y": 0.28
      },
      "kind": "list",
      "text": "ENHERTU: Redefining expectations for ADCs across breast, lung and gastric; Exciting pan-tumour potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e38f61a-5e42-4f5b-9f83-e7ab5bdc386f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.28
      },
      "kind": "list",
      "text": "IMFINZI/IMJUDO: Leadership in early-stage lung; Renewed wave of growth fueled by entry into liver and GI",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d2fbe2a-ed25-4773-a4b7-941ee684b4bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Delivering continued oncology leadership: Tumour area leadership with current medicines as established SoC; Proven track record in increasingly competitive markets; Limited LoE exposure through 2030",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4741324a-1946-4c56-96d5-be570cd7feba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.3,
        "y": 0.58
      },
      "kind": "list",
      "text": "Lynparza: Undisputed PARPi class leadership; Further growth in combinations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70d1f9e3-19fe-4b0e-b68c-ec7529496e44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.53,
        "y": 0.58
      },
      "kind": "list",
      "text": "CALQUENCE: Sustained BTKi leadership; High potential lifecycle opportunities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "924830dd-c99b-41ae-bd69-d2594b1cd9dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.3,
        "y": 0.28
      },
      "kind": "list",
      "text": "TAGRISSO: Backbone therapy for EGFRm lung cancer with strong growth outlook",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9caa01ea-c1b7-4d9a-8b77-ad946920f0e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.58
      },
      "kind": "list",
      "text": "Truqap: Delivering on the promise of AKT inhibition in breast cancer; Expansion opportunity in prostate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5cdb39e-0a59-436f-a0bc-2449b96eb689",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Rapid growth through 2023 achieving $13.5bn, +20% CER in 9M 2023",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a68e4279-0e95-4cfd-a2fc-4fc403f11b9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Oncology – clinically differentiated, high potential portfolio",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90a14633-c8e2-4480-aab6-70e6ef093b01",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "268ff9ce-affd-4ee8-b66e-4780fdc365cd",
      "evidence": "list/bullet: Delivering continued oncology leadership: Tumour area leadership with current medicines as established SoC; Proven track record in increasingly competitive markets; Limited LoE exposure through 2030",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "aadac6c5-85ff-4c00-8a67-6ccfa3236c41",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "The deck showcases AstraZeneca's successes in various disease areas, including oncology and rare disease.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4e7501eb-74e6-4ae7-8a18-04c13b6f5ddc",
      "evidence": "The deck outlines AstraZeneca's growth strategy and supporting data.",
      "position": 0,
      "objective": "How AstraZeneca's growth strategy will drive growth through 2030",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}